Haverford Trust Co Buys 14,003 Shares of Pfizer Inc. (NYSE:PFE)

Haverford Trust Co lifted its position in Pfizer Inc. (NYSE:PFE) by 2.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 516,729 shares of the biopharmaceutical company’s stock after acquiring an additional 14,003 shares during the quarter. Haverford Trust Co’s holdings in Pfizer were worth $14,877,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Briaud Financial Planning Inc purchased a new stake in Pfizer in the 3rd quarter valued at about $30,000. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer during the third quarter valued at approximately $34,000. VisionPoint Advisory Group LLC lifted its holdings in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the period. GoalVest Advisory LLC boosted its position in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in Pfizer in the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on PFE shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $35.86.

Pfizer Price Performance

Shares of PFE traded down $0.28 during midday trading on Friday, hitting $28.65. 26,090,118 shares of the company traded hands, compared to its average volume of 42,882,836. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The firm has a market cap of $162.32 billion, a P/E ratio of -477.34, a PEG ratio of 1.21 and a beta of 0.63. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock has a 50-day moving average of $27.17 and a 200-day moving average of $28.04.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.23 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.86%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.